Skip to content


Infectious Agents and Cancer

Open Access

AIDS-related Kaposi’s sarcoma: outcomes after initiation of highly active antiretroviral therapy under routine conditions in Zimbabwe

  • Bradley Nelson1Email author,
  • Margaret Borok2,
  • Tariro Makadzange2,
  • Tafadzwa Mhlanga2 and
  • Thomas Campbell1
Infectious Agents and Cancer20105(Suppl 1):A2

Published: 11 October 2010


Weight GainOpportunistic InfectionRoutine ConditionPoor Weight GainFinal Multivariate Analysis


Additional information on the outcomes of patients with AIDS-related Kaposi’s sarcoma (AIDS-KS) on highly active antiretroviral therapy (HAART) in resource-limited settings is needed. This study evaluated outcomes in AIDS-KS patients after initiation of HAART in Zimbabwe.


A retrospective cohort of 124 patients from the Parirenyatwa Hospital Kaposi’s Sarcoma and Opportunistic Infections (OI) Clinics was studied. 31 patients with AIDS-KS were matched 1:3 to 93 non-KS AIDS patients based on date of initiation of HAART, gender, and age. The primary endpoint was loss to care, defined as failure to attend clinic or refill prescriptions for 3 months or longer. Secondary endpoints were weight gain at 6 months, change in CD4+ count within 1 year, and final CD4+ count within 1 year of initiating HAART. Eligibility criteria included a minimum of 6 months of followup in the OI Clinic and less than 2 months of previous HAART prior to beginning therapy through the OI Clinic. A two-step model-selection strategy using KS status, gender, age, WHO performance status, OI disease burden, medical aid, employment, education, pre-treatment cotrimoxazole use, pre-treatment weight, and pre-treatment CD4+ count was used to identify factors associated with loss to care. On the initial univariate analysis, KS status, medical aid, and pre-treatment cotrimoxazole use had a p<0.15 and were included in the final multivariate analysis.


AIDS-KS and non-KS patients did not differ significantly in baseline characteristics except for pre-treatment CD4+ count (196 vs. 92 cells/mm3, p=0.005). On the multivariate analysis, KS status (p=0.016, HR: 4.11, CI: 1.31-12.92) and having medical aid were significant predictors of loss to care (p=0.048, HR: 3.84, CI: 1.02-14.44). At a median followup of 632 days, 37.5% of AIDS-KS patients were lost to care compared to 16.1% of non-KS patients. AIDS-KS patients had significantly worse weight gain than non-KS patients (+0.78% vs. +4.18%, p=0.023). Change in CD4+ count (p=0.149) and final CD4+ count (p=0.729) were not significantly different between study groups. Amongst AIDS-KS patients, retained patients (n=20) had significantly higher pre-treatment CD4+ counts than patients lost to care (n=11) (232 vs. 122 cells/mm3, p=0.048).


After initiating HAART, AIDS-KS patients experienced greater loss to care and poorer weight gain than matched non-KS patients, suggesting that, under routine conditions in Zimbabwe, AIDS-KS patients have worse intermediate- and long-term clinical outcomes than non-KS AIDS patients. AIDS-KS patients retained in care had higher pre-treatment CD4+ counts than patients lost to care, indicating that early intervention with HAART may improve outcomes in AIDS-KS patients.



This article has been published as part of Infectious Agents and Cancer Volume 5 Supplement 1, 2010: Proceedings of the 12th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI).The full contents of the supplement are available online at

Authors’ Affiliations

Department of Medicine, University of Colorado, Denver, USA
Department of Medicine, University of Zimbabwe, Harare, Zimbabwe


© Nelson et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd.